Zobrazeno 1 - 10
of 182
pro vyhledávání: ''
Autor:
Markus W. Büchler, Benedikt Wagner, J Klose, Maik Brune, Martin Schneider, Lukas F. Liesenfeld, Thomas Schmidt, H. Christian Hillebrecht, Christoph Eckert
Publikováno v:
Annals of Surgical Oncology
Background Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) is the treatment of choice for selected patients with peritoneal malignancies. HIPEC is accompanied by moderate-to-high patient morbidity, includin
Publikováno v:
Pharmacological Reports
Background Intense statin therapy was found to impair testosterone production in men. Metformin administered to subjects with hypergonadotropic hypogonadism decreased gonadotropin production. The current study was aimed at investigating whether metfo
Publikováno v:
Neuropsychopharmacology
Synaptic dysfunction is a likely proximate cause of subtle cognitive impairment in early Alzheimer’s disease. Soluble oligomers are the most synaptotoxic forms of amyloid ß-protein (Aß) and mediate synaptic plasticity disruption in Alzheimer’s
Publikováno v:
Drugs
Sphingosine-1-phosphate (S1P) is a bioactive lipid metabolite that exerts its actions by engaging 5 G-protein-coupled receptors (S1PR1-S1PR5). S1P receptors are involved in several cellular and physiological events, including lymphocyte/hematopoietic
Autor:
Nuran Katgi, Z. Andric, Elena Poddubskaya, Rita de Cassia Costamilan, Chaiyut Charoentum, Eduardo P Yañez Ruiz, Tamta Makharadze, Andrea Fulop, Susana Millan, D. Trukhin, Ana Del Campo García, Ravi Shankar Bellala, Yamil Alonso Lopez Chuken, Kostas N. Syrigos, Alexandra Paravisini, Amalia Florez, Jasmin Reyes-Igama, Irfhan Ali Hyder Ali, Stella Investigators, Ilieva Rumyana
Publikováno v:
Biodrugs
Background MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab). Objectives To confirm clinical similarity between MB02 and EU-bevacizumab, a comparab
Autor:
Francesco Raspagliesi, Maurizio D'Incalci, Cristina Matteo, Sara Cresta, Tommaso Ceruti, Giuseppa Maltese, Ilaria Sabatucci, Serena Giolitto, Massimo Zucchetti, Domenica Lorusso, Cristina Sonetto, Dominique Ronzulli, Filippo de Braud, Valentina Sinno
Publikováno v:
Targeted Oncology
Background Targeted agents, such as antiangiogenic drugs (e.g., bevacizumab) and poly(ADP-ribose) polymerase inhibitors (e.g., rucaparib), have been shown to improve outcomes in patients with newly diagnosed or recurrent ovarian cancer. Evidence sugg
Autor:
Spinello Antinori, Dario Cattaneo, Letizia Oreni, Alice Covizzi, Aldo P. Maggioni, Andrea Giacomelli, Cristina Gervasoni, Annalisa Ridolfo, Marco Schiuma, Luca Pasina, Lucia Bradanini
Publikováno v:
Drugs & Aging
Background Patients hospitalised with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co-morbidities and receiving polypharmacy, all of which are known risk factors
Autor:
Alexis Revet, Antoine Yrondi, François Montastruc, Yannick Degboé, Philippe Garcia, Vanessa Rousseau
Publikováno v:
Drug Safety
Introduction In the stressful context of the coronavirus disease 2019 (COVID-19) pandemic, some reports have raised concerns regarding psychiatric disorders with the use of hydroxychloroquine. In this study, we reviewed all psychiatric adverse effect
Publikováno v:
Clinical Drug Investigation
Clinical drug investigation, vol 40, iss 10
Clinical drug investigation, vol 40, iss 10
Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality both in the USA and globally. As the burden of CAP continues to increase due to several factors, the advances in its diagnosis, prevention, and treatment have taken on eve
Publikováno v:
Hormones (Athens, Greece)
Purpose Estrogens have beneficial effects on the cardiovascular system, promoting vasodilation, endothelial cells growth, relaxation, and regulation of blood pressure. Some of these effects could be associated with the purinergic system known for the